Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 52 |
| Active Pipeline (Recruiting Now) | 24 (18) |
| Completed vs Stopped Early | 19 / 9 (17.3%) |
| Median Closed Actual Enrollment | 28 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Cincinnati Children's Hospital Medical Center | Cincinnati, OH | 35 |
| Nationwide Children's Hospital | Columbus, OH | 3 |
| Children's Hospital Colorado | Aurora, CO | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05538208 | The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study | Phase II | RECRUITING |
| NCT05660746 | Precise Infliximab Exposure and Pharmacodynamic Control | Phase II/III | RECRUITING |
| NCT03678545 | Dupilumab in Eosinophilic Gastritis | Phase II | COMPLETED |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Cincinnati Children's Hospital Medical Center across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Children's Hospital Medical Center, Cincinnati Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.